bluuebunny/crossref_metadata_2025_split huggingface dataset:
NCMP-16. CNS METASTATIC PATTERNS IN BREAST CANCER TREATED WITH CDK4/6 INHIBITORS: PRELIMINARY RESULTS OF A RETROSPECTIVE ANALYSIS
Authors: Bazer Danielle A , Reiss Justus , Sherief Mohamed , Zhou Yuan , Martinez Daniel Heinemann , Parampil Amy , Torroella Jordina Rincon , Wolff Antonio C , Couzi Rima , Stearns Vered , Wilkinson Mary , Jelovac Danijela , Tao Jessica , Sheng Jenni , Canzoniero Jenna V , Santa-Maria Cesar , Kamson David O , Sahebjam Solmaz 
Published: November 2024

Abstract

BACKGROUND
CDK4/6 inhibitors combined with hormonal therapy or as monotherapy (abemaciclib) play an important role in the management of hormone receptor positive, HER-2 negative breast cancer (BC). To date, these drugs were shown to improve progression-free survival, whereas their comparative effect modulating breast cancer central nervous system metastases (CNSm) has not yet been extensively studied. Here, we present the early findings and analytic plan of our retrospective study to evaluate CNSm patterns and differences among CDK4/6-inhibitors in BC.

METHODS
In this retrospective chart review study, we queried the Johns Hopkins Electronic Medical Record from 1/1/2014 to 4/25/2024 using the following prescreening criteria: 1) Age ≥18 years; 2) Diagnosis and/or problem list including BC; 3) Palbociclib, abemaciclib, or ribociclib included in the medication list. The identified patients were dichotomized based on the presence/absence of ICD10 codes for CNSm and are currently being chart-reviewed. Patients without longitudinal data or confirmed CNS or with CNSm diagnosed before/within 1 month of CDK-inhibitor initiation were excluded. Population: Prescreening identified 1,419 patients (1,055 palbociclib, 301 abemaciclib, 145 ribociclib) of whom 239, 36, and 19 patients had ICD10 codes for brain metastases, respectively. After exclusion of false positives from this cohort, we confirmed 53 patients with CNSm in the palbociclib, 3 in the ribociclib, and 1 in the abemaciclib group.

RESULTS
We present the current data from the first-line palbociclib cohort (N=53) where, median time to CNSm on was 24 months (interquartile range 13-46). Fifty-two (98.1%) patients had documented bone, 31 (58.5%) dural, 7 (13.2%) leptomeningeal, and 33 (62.3%) calvarial involvement. Dural and calvarial metastases were strongly associated with each other (pearson-chi2=10.7; p=0.001).

CONCLUSIONS
This is a work-in-progress, with early preliminary findings showing a high rate of dural and calvarial metastases in this cohort. A more detailed review of the dataset that will also include the CNS-metastasis-free cohort is underway.
NCMP-21. COMPARATIVE ANALYSIS OF VENTRICULOPERITONEAL SHUNT PLACEMENT FOR POST-TREATMENT HYDROCEPHALUS FOLLOWING VESTIBULAR SCHWANNOMA MANAGEMENT: SURGICAL INTERVENTION VERSUS STEREOTACTIC RADIOSURGERY
Authors: Akhavan-Sigari Amirhossein , Persad Amit R L , Kattaa Ahed H , Hori Yusuke S , Emrich Sara C , Ustrzynski Louisa , Tayag Armine , Park David J , Chang Steven D 
Published: November 2024

Abstract

INTRODUCTION
Hydrocephalus may present in patients with vestibular schwannoma (VS) at initial diagnosis, primarily due to the obstructive effects of tumor mass on cerebrospinal fluid (CSF) dynamics. Notably, occurrences of hydrocephalus following either radiosurgery or surgical interventions have also been documented in clinical literature.

OBJECTIVE
To compare the clinical features of patients who have undergone surgical resection or radiosurgery for VS and subsequently developed hydrocephalus necessitating shunt placement.

METHODS
We conducted a retrospective analysis of patients diagnosed with VS who underwent management via surgery or radiosurgery at Stanford Medical Center between 1998 and 2024, focusing on those who subsequently required shunt placement.

RESULTS
A total of 30 patients with VS underwent shunt placement due to hydrocephalus after tumor treatment; 5 patients (16.7%) were managed with radiosurgery and 25 patients (83.3%) with surgery. The median age at treatment was 64 years versus 57 years for the radiosurgery and surgery groups, respectively. There were no significant differences in age, sex, tumor volume, largest diameter at treatment, and tumor Koos grades, between the two groups. Nonetheless, the median time from tumor treatment to shunt placement was significantly longer in the radiosurgery group compared to the surgery group (21.53 versus 1.17 months, p-value=0.002). Regarding CSF parameters, mean white blood cell (WBC) and red blood cell (RBC) counts prior to shunt placement was significantly higher in the surgery versus the radiosurgery group (WBC=83.6 versus 2.0/mm3, p-value=0.001, RBC=3453.4 versus 313.33/mm3, p-value=0.02). CSF protein and glucose were not significantly different between the groups.

CONCLUSION
The median time from VS treatment to shunt placement due to hydrocephalus was longer in the radiosurgery group compared to the surgery group. Furthermore, pre-shunt CSF WBC and RBC counts were higher in the surgery group. Future studies are needed to better understand treatment outcomes and optimize management strategies for these patients.
NCMP-22. CO-OCCURRENCE OF MULTIPLE SCLEROSIS AND HODGKIN LYMPHOMA. IS THERE A COMMON PATHOPHYSIOLOGY?
Authors: Garg Ipshita , Agyei Paunel , Gálvez-Jiménez Néstor , Ranjan Surabhi 
Published: November 2024

Abstract

BACKGROUND
Multiple sclerosis (MS) and Hodgkin lymphoma (HL) share common epidemiology, genetics and immunological factors. Both affect immune activation, cell proliferation and lymphocyte-mediated immunity. However, occurrence of these two distinct clinical conditions is rare. We present a case of a woman with transverse myelitis fulfilling criteria for MS with synchronous HL.

CASE REPORT
A 37-year-old woman presented to the emergency room with bilateral leg weakness, numbness and urinary retention. A contrasted MRI of the brain and thoracic spine showed non-specific, non-enhancing white-matter lesions in the brain, and patchy areas of peripheral contrast-enhancement with T2-hyperintensity in the thoracic cord. Treatment with steroid infusion resulted in mild improvements of leg weakness and numbness. Cerebrospinal fluid (CSF) demonstrated oligoclonal bands (OCB) and increased IgG index. Serum was positive for JCV antibody. Due to the atypical MRI findings, namely the peripheral nature of thoracic contrast-enhancement, we were concerned for other inflammatory or autoimmune etiologies. A computed tomography of the chest, abdomen and pelvis revealed a large mediastinal mass and enlarged lymph nodes. A biopsy revealed classic HL. Three-months later, a follow-up MRI brain showed worsening contrast-enhanced lesions. A repeat CSF study revealed normal OCBs and IgG index. CSF was negative for malignant cells and JC virus DNA. To rule out a rare possibility of central nervous system HL, a biopsy of an enhancing brain lesion was obtained, which showed focal gliosis and focal perivascular lymphocytic infiltrates. No malignant cells were observed. She was diagnosed with multiple sclerosis and started systemic chemotherapy (doxorubicin, bleomycin, dacarbazine and vinblastine) for HL.

CONCLUSIONS
We report a case of an atypical transverse myelitis with HL. Although familial genetic clustering has been described, other potential common risk-factors between MS and HL are Epstein-Barr Virus infection and immunologic overlap, particularly in the context of lymphocyte-mediated immunity.
NCMP-24. GLIOMA-RELATED EPILEPSY: ANTI-SEIZURE REGIMENS, TOLERABILITY AND SYMPTOM BURDEN
Authors: Patel Shrey , Akintola Oluwatosin 
Published: November 2024

Abstract

AIMS
Seizures are often the presenting symptom in 30-40% of glioma patients, and play a significant role in patients’ quality of life and symptom burden. Many complex factors are considered when selecting anti-seizure medications (ASM) for the individual patient. This single institution study investigates physician practices, seizure control and adverse effect profiles of ASM regimens in glioma patients.

METHOD
A retrospective review was undertaken of the electronic health records of glioma patients from 2020-2022 who were followed at the University of Vermont Medical Center.

RESULTS
Ninety-four patients (90 glioblastoma IDH-WT, 1 astrocytoma, 2 oligodendroglioma, 1 radiological diagnosis of glioma) were included. Levetiracetam was the first line ASM in 93 patients including seizure prophylaxis patients per neurosurgical practice. 30 of the patients presented with seizures and required long term ASMs. 21 required a second-line ASM, 3 required a third-line ASM, and 20 experienced at least one adverse drug effect. 11.4% of patients experienced mood disturbances on levetiracetam, ranging from anxiety to mania. 5% of patients experienced generalized weakness and gait imbalance issues on levetiracetam. 25% of patients experienced breakthrough seizures over the course of their illness despite therapeutic levetiracetam &gt; 1000mg/day. 10.4% of patients presented with breakthrough status epilepticus following the initiation of levetiracetam therapy. No statistically significant differences were seen in rates of breakthrough seizures based on extent of resection, functional status or sex.

CONCLUSIONS
Seizures are a major cause of morbidity in glioma patients. The overwhelming majority of patients included in this study were placed on levetiracetam as a first-line ASM. Most patients on long-term levetiracetam experienced at least one neuropsychiatric adverse effect. Further studies are required to investigate the efficacy and tolerability of ASM regimens in glioma patients and to understand methods for ASM regimen individualization for varying disease courses.
NCMP-27. NEUROLOGICAL COMPLICATIONS IN LUNG CANCER THERAPIES: UNVEILING THE ELEVATED RISKS IN CHEMOTHERAPY AND TARGETED TREATMENT APPROACHES
Authors: Manne Swetha , Currie Joshua 
Published: November 2024

Abstract

BACKGROUND
Neurological complications due to lung cancer treatments are a common side effect, with prevalence ranging from 19% to over 80% depending on the drug administered. Peripheral neuropathy is the most common manifestation of chemotherapy associated neurotoxicity, but there are potential central nervous system impacts as well, such as seizures, dementia, and generalized cognitive impairment. Occurrence of similar effects is less commonly reported with targeted gene therapy for cancer, however the exact prevalence has not been determined.

DESIGN/METHODS
We searched the US Collaboration network through TriNetX for all cases of lung cancer, identified by ICD-10 code C34. Cohort A was defined as adults 18-70 years old that had lung cancer treated with cisplatin or etoposide. Cohort B was defined as adults 18-70 that had lung cancer treated with crizotinib, alectinib, or epidermal growth factor receptor tyrosine kinase inhibitors. Outcomes were evaluated from 1 day to 5 years after the indexed event.

RESULTS
We reported 15,268 patients with lung cancer that were prescribed chemotherapy agents matched with 6,490 patients with lung cancer that were prescribed tyrosine kinase inhibitors. Patients prescribed chemotherapy agents were at significantly higher risk for neurological complications post treatment when compared to those treated with tyrosine kinase inhibitors (p &lt; 0.0001).

CONCLUSIONS
Patients diagnosed with lung cancer on chemotherapy 18-70 years old displayed higher associated risk of various neurological disorder diagnoses. Patients undergoing chemotherapy should be educated about this increased risk and talk with their providers about alternative treatments. Further research should be conducted on the range of potential neurological complications associated with chemotherapy regimens.
NCMP-29. BRAIN LESIONS IN A TEEN WITH NEWLY DIAGNOSED T-CELL ALL AND SARS-COV-2 INFECTION
Authors: Aspromonte Salvatore , Ehidom Clinton , Khan Shama , Perez Julio Arevalo , Pascual Juan , Greenfield Jeffrey , Hohl Tobias , Haque Sofia , Khakoo Yasmin , Trippett Tanya 
Published: November 2024

Abstract
T-cell Lymphoblastic Leukemia (T-cell ALL) accounts for up to 15% of all newly diagnosed cases of acute lymphoblastic leukemia in pediatric patients (0-18 years old). Patients are at risk of opportunistic infections during induction therapy with up to 2% developing blood stream infections when their absolute neutrophil count is above 1,500. We report a case of a 15-year-old female with High-Risk T-cell ALL, CNS1 (negative CNS disease), presenting with three days of headaches, photophobia, and non-neutropenic fever. She completed induction chemotherapy one week earlier with vincristine, daunorubicin, calaspargase and a 28-day course of dexamethasone. On physical exam, she had no focal deficits or changes in sensation or strength. CBC was notable for a white blood cell count: 7500, hemoglobin: 8.6, platelets: 328,000 and ANC (Absolute Neutrophil Count): 4700. The patient was also COVID positive on admission. A contrast enhanced MRI brain demonstrated multiple diffusion restricting and peripherally enhancing lesions, concerning for intracranial abscesses. Neurosurgery performed a burr hole craniotomy and aspirated 5 mL of purulent drainage, the culture of which grew Aspergillus fumigatus complex. The patient was started empirically on Voriconazole, in addition to broad spectrum antibiotic coverage pending culture results, due to excellent CNS penetration and proven superiority to amphotericin-based therapy for invasive aspergillosis. Micafungin was added due to CT chest demonstrating nodular infiltrates, suggesting primary pulmonary aspergillosis with CNS dissemination. The patient improved symptomatically without further sequelae. Patients with COVID-19 on prolonged courses of corticosteroids are at higher risk of developing fungal co-infections regardless of neutrophil count. While pulmonary aspergillosis is the most common location of a COVID-19 aspergillus coinfection, there have been documented reports of intracranial micro-abscesses. Contrast-enhanced brain MRI should be obtained in any patient with a recent history of COVID-19 presenting with new neurological symptoms, especially in a patient with a recent history of corticosteroids.
NCOG-08. A RARE PRIMARY CNS T-CELL LYMPHOMA CASE: 12-YEAR FOLLOW-UP AFTER CHEMOTHERAPY
Authors: Cheng Amory , Bota Daniela A , Kong Xiao-Tang 
Published: November 2024

Abstract

INTRODUCTION
Primary central nervous system (CNS) T-cell lymphoma (PCNSTL) is a rare hematological malignancy. There is mere literature to guide the treatment.

CASE REPORT
This study is an update on our previously reported case at SNO in 2012 after a 12-year follow-up, detailing the long-term outcome of our chemotherapy treatment for a case of PCNSTL. In 2011, a 26-year-old immunocompetent patient presented with severe headache, vomiting, and lethargy. The brain MRI found more than a dozen masses on his bilateral cerebral hemispheres. Brain biopsy discovered T-cell lymphoma. The patient was started biweekly high-dose-methotrexate (HD-MTX) in 2011. After three doses, there was no noticeable improvement on his brain MRI. His treatment was switched to HD-MTX plus high dose cytarabine regimen (Ferreri et al, The Lancet, 2009). The patient could not tolerate cytarabine; thus, was changed back to HD-MTX. The patient responded to the rest of HD-MTX well. He completed 8 doses of biweekly HD-MTX induction therapy and 2 doses of monthly HD-MTX maintenance therapy. His brain MRI showed complete resolution of enhancement on one-year follow-up image. The patient has been off-treatment and monitored under surveillance of brain MRIs since 2012. He has had no lymphoma recurrence over the past 12 years. His physical functions have been preserved with a Karnofsky Performance Status scale of 80%. Neuropsychological evaluations in 2015, 2018, and 2023 showed mild cognitive impairment with gradual improvements in his working memory and semantic fluency. His Mini-Mental Status Exam scores have remained stable to mild improvement, recording 27/30 in 2015, 26/30 in 2018, 27/30 in 2023 and 28/30 in 2024.

DISCUSSION
The patient, who is now 38 years old, has surpassed a 12-year survival mark. Our experience emphasizes the feasibility of treating PCNSTL through chemotherapy only, which might be potentially beneficial in surviving and preserving major aspects of brain function.
NCOG-13. ASSESSING CAREGIVER OUTCOMES OF PRIMARY BRAIN TUMOR PATIENTS: A SYSTEMATIC REVIEW OF THE LITERATURE
Authors: Walbert Tobias , Cachia David , Hertler Caroline , Sherwood Paula , Dirven Linda , Young Jacob , Stockdill Macy , Almaraz Eduardo Rodriguez , Pill Karin , Boele Florien 
Published: November 2024

Abstract

BACKGROUND
Family caregivers in neuro-oncology are known to have high levels of unmet support needs. Intervention trials and effective support options are scarce. The Response Assessment in Neuro-Oncology (RANO-) Cares working group has been established to determine standards of caregiver outcomes (CO) research reporting in neuro-oncology. We present the current state of methodological quality of reporting on neuro-oncology caregiver outcomes in randomized controlled trials (RCTs).

METHODS
A systematic literature review (PubMed/Medline, Embase, Web of Science, Emcare, Cochrane Library, PsycINFO; July 2023) was performed to assess to what degree RCTs assessing outcomes of family caregivers of adult primary brain tumor patients adhere to established reporting standards. Using Covidence, screening and data extraction was independently performed by two researchers, with a third guiding consensus. A 33-item checklist (23 applicable to secondary analysis reports) based on the International Society for Quality of Life (ISOQOL) Research criteria for patient-reported outcome reporting was utilized to assess reporting standards. Risk of bias was assessed per RCT.

RESULTS
Fifteen publications (12 unique RCTs) included 684 neuro-oncology caregivers, with low overall risk of bias. Ten publications (66%) reported on COs as a primary aim and eight (80%) of these satisfied ≥2/3 of the key methodological criteria. Of the five secondary analysis reports (33%) two met ≥2/3 of applicable key criteria. Criteria often missed are related to sample size calculations, details on statistical approaches, discussion of limitations and clinical significance of studies. Only three of the 12 RCTs were definitive trials aimed at improving COs and five should be considered as pilot or feasibility studies.

CONCLUSION
RCTs investigating neuro-oncology COs have high reporting standards and risk of bias was low. Future studies should focus on specific caregiver interventions to reduce high caregiver burden and with that patients’ quality of life.
NCOG-14. THE ROLE OF POSTOPERATIVE BLOOD PRESSURE MANAGEMENT IN EARLY POSTOPERATIVE HEMORRHAGE IN AWAKE CRANIOTOMY GLIOMA PATIENTS
Authors: Kerschbaumer Johannes , Demetz Matthias , Kriger Aleksandrs , Pinggera Daniel , Klingenschmid Julia , Thomé Claudius , Freyschlag Christian 
Published: November 2024

Abstract

INTRODUCTION
Awake surgery is widely used to maximize the extent of resection and enhance neuro-oncological outcome in gliomas. Postoperative hemorrhage can severely deteriorate the patients’ neurological outcome. Higher postoperative blood pressure can increase the risk of postoperative hemorrhage, but optimal perioperative patient and blood pressure management is unclear. The aim of this study was to investigate the role of postoperative blood pressure and other common radiological and epidemiological features with the incidence of postoperative hemorrhage.

MATERIAL & METHODS
In this retrospective analysis, we included all patients who underwent awake surgery between 2010 and 2023 at our institution. We assessed the blood pressure both intra- and postoperatively as well as the heart rate for the first 12 hours. We compared a cohort with postoperative hemorrhage, who required further treatment (surgical revision or intravenous antihypertensive therapy), with a cohort with no postoperative hemorrhage.

RESULTS
We included 48 patients with a median age of 39 years. 9 patients (19%) showed a preoperative history of arterial hypertension, 8 of them were on antihypertensive treatment. 23 patients (48%) showed signs of a hemorrhage on early postoperative MRI, of whom 9 (19%) required further treatment, which was surgery in 2 cases and conservative therapy in 7 cases. Patients with postoperative hemorrhage showed significantly higher postoperative systolic blood pressure during the hours 3-12 (p&lt;0.05) as well as intraoperatively during the hours 1-5 (p&lt;0.05). In ROC and Youden Test, a strong impact of systolic blood pressure over 140 mmHg during the early postoperative course could be shown.

DISCUSSION
Postoperative hemorrhage is a serious complication in awake surgery glioma patients. However, with early treatment, no significant difference in Performance scores at follow-up could be found. To avoid postoperative hemorrhage, treating physicians should aim strictly on systolic blood pressure of under 140 mmHg for the postoperative course.
NCOG-18. META-ANALYSIS OF DIRECT ENDOVASCULAR THROMBECTOMY VS BRIDGING THERAPY IN THE MANAGEMENT OF ACUTE ISCHEMIC STROKE WITH LARGE VESSEL OCCLUSION
Authors: Shafique Muhammad Ashir , Lucke-Wold Brandon , Mustafa Muhammad Saqlain , Ali Syed Muhammad Sinaan 
Published: November 2024

Abstract

Debates persist when using intravenous thrombolysis (IVT) before mechanical thrombectomy (MT) for acute ischemic stroke (AIS) due to large-vessel occlusion (LVO). This systematic review and meta-analysis synthesized evidence on outcomes in patients with acute ischemic stroke due to large vessel occlusion (AIS-LVO), comparing bridging therapy (BT) with MT alone.

METHOD
We conducted searches of PubMed, Scopus, Web of Science, and the Cochrane Central Register of Controlled Trials from inception to July 2023 to identify pertinent clinical trials and observational studies.

RESULT
76 studies, involving 37,658 patients, revealed no significant difference in 90-day functional independence between DEVT and BT. However, a trend favoring BT for achieving functional independence with a modified Rankin Scale (mRS) of 0–1 was observed, having Odds ratio (OR) of 0.75 (95% CI 0.66–0.86; p &lt; 0.001). DEVT was associated with higher postprocedural mortality (OR 1.44;95% CI 1.25–1.65; p &lt; 0.001), but a lower risk of symptomatic intracranial hemorrhage compared to BT (OR 0.855; 95% CI 0.621–1.177; p = 0.327). Successful recanalization rates favored BT, emphasizing the importance of individualized treatment decisions (OR 0.759; 95% CI 0.594–0.969; p = 0.027). Sensitivity analyses were conducted to identify key contributors to heterogeneity.

CONCLUSION
Our meta-analysis underscores the intricate equilibrium between functional efficacy and safety in the evaluation of DEVT and BT for ACS-LVO. Fundamentally, while BT appears more efficacious, concerns about safety arise due to the superior safety profile demonstrated by DEVT. Individualized treatment decisions are imperative, and further trials are warranted to enhance precision in clinical guidance.